SG10201914002RA - Humanized universal light chain mice - Google Patents

Humanized universal light chain mice

Info

Publication number
SG10201914002RA
SG10201914002RA SG10201914002RA SG10201914002RA SG10201914002RA SG 10201914002R A SG10201914002R A SG 10201914002RA SG 10201914002R A SG10201914002R A SG 10201914002RA SG 10201914002R A SG10201914002R A SG 10201914002RA SG 10201914002R A SG10201914002R A SG 10201914002RA
Authority
SG
Singapore
Prior art keywords
light chain
universal light
chain mice
humanized universal
humanized
Prior art date
Application number
SG10201914002RA
Inventor
John Mcwhirter
Lynn Macdonald
Sean Stevens
Samuel Davis
David Buckler
Karolina Hosiawa
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201914002RA publication Critical patent/SG10201914002RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
SG10201914002RA 2011-08-05 2012-08-03 Humanized universal light chain mice SG10201914002RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515374P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
SG10201914002RA true SG10201914002RA (en) 2020-03-30

Family

ID=46650953

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201606158TA SG10201606158TA (en) 2011-08-05 2012-08-03 Humanized universal light chain mice
SG2014007686A SG2014007686A (en) 2011-08-05 2012-08-03 Humanized universal light chain mice
SG10201914002RA SG10201914002RA (en) 2011-08-05 2012-08-03 Humanized universal light chain mice

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201606158TA SG10201606158TA (en) 2011-08-05 2012-08-03 Humanized universal light chain mice
SG2014007686A SG2014007686A (en) 2011-08-05 2012-08-03 Humanized universal light chain mice

Country Status (25)

Country Link
US (3) US10130081B2 (en)
EP (3) EP3572517B1 (en)
JP (6) JP6510234B2 (en)
CN (2) CN107602696B (en)
AU (4) AU2012294624B2 (en)
BR (1) BR112014002713B1 (en)
CA (1) CA2844070A1 (en)
CY (2) CY1122435T1 (en)
DK (2) DK2739740T3 (en)
ES (2) ES2758051T3 (en)
HR (2) HRP20192255T1 (en)
HU (2) HUE047278T2 (en)
IL (4) IL273982B2 (en)
LT (2) LT3572517T (en)
MX (2) MX357623B (en)
MY (1) MY172718A (en)
NZ (3) NZ727084A (en)
PL (2) PL2739740T3 (en)
PT (2) PT3572517T (en)
RS (2) RS59728B1 (en)
RU (1) RU2664232C2 (en)
SG (3) SG10201606158TA (en)
SI (2) SI2739740T1 (en)
WO (1) WO2013022782A1 (en)
ZA (1) ZA201401006B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
LT3241435T (en) 2009-07-08 2021-10-25 Kymab Limited Animal models and therapeutic molecules
MX350983B (en) 2010-02-08 2017-09-27 Regeneron Pharma Common light chain mouse.
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
IN2013CN07629A (en) 2011-02-25 2015-08-07 Regeneron Pharma
RU2664232C2 (en) * 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL2627773T3 (en) 2011-10-17 2017-11-30 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
EP3527070A1 (en) 2011-12-20 2019-08-21 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
SG11201404477YA (en) * 2012-02-01 2014-08-28 Regeneron Pharma HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS
HUE053310T2 (en) 2012-03-16 2021-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents for generating the same
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
PL2825037T4 (en) 2012-03-16 2020-03-31 Regeneron Pharmaceuticals, Inc. Rodents expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR20150023535A (en) * 2012-06-05 2015-03-05 리제너론 파마슈티칼스 인코포레이티드 Methods for making fully human bispecific antibodies using a common light chain
US10238093B2 (en) * 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
CN108611369B (en) * 2013-03-13 2022-08-26 瑞泽恩制药公司 Mice expressing restricted immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2859373T3 (en) 2013-10-01 2021-10-01 Kymab Ltd Animal models and therapeutic molecules
US10034463B2 (en) 2014-01-24 2018-07-31 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR20230158661A (en) 2014-03-21 2023-11-21 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
AU2016232715A1 (en) * 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2017035241A1 (en) * 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
CN105274116B (en) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 Nucleic acid molecule for preparing humanized antibody and application thereof
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
CN109071633B (en) 2016-04-20 2022-11-18 瑞泽恩制药公司 Compositions and methods based on the use of expression enhancing loci for the production of antibodies
JP7324583B2 (en) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for breaking immune tolerance using multiple guide RNAs
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
EA201991673A1 (en) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CN117099741A (en) 2019-02-18 2023-11-24 百奥赛图(北京)医药科技股份有限公司 Genetically modified non-human animals with humanized immunoglobulin loci
BR112021023683A2 (en) 2019-06-05 2022-02-01 Regeneron Pharma Genetically modified rodent and mouse, rodent embryo, genetically modified rodent or mouse b-cell, hybridoma, b-cell population, embryonic stem cell, mammalian cell, methods of producing an antibody, a heavy chain, a domain variable, from a collection of variable domains, from a light chain, from a nucleotide sequence, from a genetically modified rodent and from es cells, from generating a variable domain and in vitro to generate a recombinant rodent cell, and, vector of direction
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
US10994021B1 (en) * 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
CN115988960A (en) * 2020-06-25 2023-04-18 株式会社湖美宝 Hybrid transgenic animals
TW202229328A (en) 2020-09-11 2022-08-01 美商再生元醫藥公司 Identification and production of antigen-specific antibodies
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4326765A1 (en) 2021-04-20 2024-02-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
CN117587070B (en) * 2024-01-19 2024-04-30 北京仁源欣生生物科技有限公司 Preparation method and application of genetically modified non-human mammal

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
CA1341351C (en) 1988-09-06 2002-03-26 Marc D. Better Production of chimeric mouse-human antibodies with specificity to human tumor antigens
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DK0502976T3 (en) 1989-12-01 1996-11-11 Pharming Bv Production of recombinant polypeptides by bovine species and transgenic methods
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
JPH08503617A (en) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Humanized antibody reactive with L-selectin
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
JPH08509612A (en) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU1595195A (en) 1993-12-23 1995-07-10 Abs Global, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
GB9401380D0 (en) 1994-01-25 1994-03-23 Pharmaceutical Proteins Ltd Embryonic cell isolation
ES2201097T3 (en) 1994-01-31 2004-03-16 Trustees Of Boston University POLYCLONAL ANTIBODIES LIBRARIES.
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
ES2176574T3 (en) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY.
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
AU745334B2 (en) 1997-03-06 2002-03-21 Advanced Cell Technology, Inc. Method of cloning animals
CN1203922A (en) 1997-03-21 1999-01-06 三共株式会社 Humanized anti-human fas antibody
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
DE69838454T2 (en) 1997-10-03 2008-02-07 Chugai Seiyaku K.K. NATURAL HUMAN ANTIBODY
ATE302271T1 (en) 1997-11-18 2005-09-15 Pioneer Hi Bred Int COMPOSITIONS AND METHODS FOR GENETIC MODIFICATION OF PLANTS
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
RU10506U1 (en) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич MANUAL CULTIVATOR
PT1533380E (en) 1999-04-15 2010-02-09 Crucell Holland Bv Recombinant protein production in a human cell comprising at least one e1 protein of adenovirus
EP1183344A4 (en) 1999-05-27 2003-06-25 Human Genome Sciences Inc Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
WO2001064929A1 (en) 2000-02-29 2001-09-07 Auburn University Production of antibodies in transgenic plastids
RU2262511C2 (en) 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Humanized monoclonal antibody raised against ailim, co-stimulating molecule for signal transfer and its pharmaceutical applying
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004504055A (en) 2000-07-21 2004-02-12 アメリカ合衆国 Methods of DNA replacement, translocation and stacking in eukaryotic genomes
MXPA03001915A (en) 2000-08-03 2004-09-10 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals.
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7449179B2 (en) 2000-11-16 2008-11-11 Cornell Research Foundation, Inc. Vectors for conditional gene inactivation
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
DE10064750A1 (en) 2000-12-22 2002-06-27 Bayer Ag Production of 1,6-hexane diol for use in polyester or polyurethane production involves reacting formaldehyde with propene to form a homo-allyl alcohol, catalytic metathesis to 3-hexene-1,6-diol and catalytic hydrogenation
CZ301712B6 (en) 2001-01-05 2010-06-02 Pfizer Inc. Antibody to IGF-I receptor and pharmaceutical composition containing such antibody
US6961875B2 (en) 2001-03-22 2005-11-01 International Business Machines Corporation Method and apparatus for capturing event traces for debug and analysis
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
CN100448992C (en) 2001-05-11 2009-01-07 麒麟医药株式会社 Artificial human chromosome containing human antibody lambda light chain gene
DE60237282D1 (en) 2001-06-28 2010-09-23 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND ITS USE
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
EP1652920B1 (en) 2001-10-01 2010-08-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods of producing protein libraries and selection of proteins from them
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
DK2319301T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
US20050095712A1 (en) 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
WO2003059952A1 (en) 2002-01-18 2003-07-24 Inovio As Bispecific antibody dna constructs for intramuscular administration
JP4518941B2 (en) 2002-04-26 2010-08-04 中外製薬株式会社 Agonist antibody screening method
US20040023880A1 (en) 2002-05-03 2004-02-05 Gale Nicholas W. Methods of inducing formation of functional and organized lymphatic vessels
JP5139626B2 (en) 2002-06-14 2013-02-06 イミューノメディクス、インコーポレイテッド Monoclonal antibody hPAM4
CN101962408A (en) 2002-07-12 2011-02-02 杰斐逊·富特 Super-humanized antibody
CA2965865C (en) * 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
AR042145A1 (en) 2002-11-27 2005-06-08 Dow Agrociences Llc IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
JP4966006B2 (en) 2003-01-28 2012-07-04 セレクティス Custom-made meganucleases and their use
JP2006520610A (en) 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Vector used to produce hybrid constant region
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
MXPA06000562A (en) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Humanized immunoglobulin loci.
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (en) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Method for early and preclinical diagnostics of cervical cancer
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
ATE504599T1 (en) 2004-01-16 2011-04-15 Regeneron Pharma FUSION POLYPEPTIDES CAPABLE OF ACTIVATING RECEPTORS
CA2561504C (en) 2004-02-12 2015-05-12 The Walter And Eliza Hall Institute Of Medical Research Modified cells that co-express blimp1 and a reporter molecule and methods of using the same
CN1560081A (en) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 Preparing human source monoclone antibody by mouse capable of producing human IgGl weight chain-k light chain and application thereof
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
WO2006047367A2 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
CA2585043A1 (en) * 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
EP1662005A1 (en) 2004-11-26 2006-05-31 FrankGen Biotechnologie AG Enhancer-containing gene trap vectors for random and targeted gene trapping
CA2589208A1 (en) 2004-11-26 2006-06-01 Frankgen Biotechnologie Ag Gene trap cassettes for random and targeted conditional gene inactivation
US20110041370A1 (en) 2005-04-21 2011-02-24 Saint Andre M Face sheet, identification band, and related methods
JP2008538912A (en) 2005-04-29 2008-11-13 イナート・ファルマ Transgenic animal and method for producing recombinant antibody
AU2005331864A1 (en) 2005-05-14 2006-11-23 Fudan University Piggybac as a tool for genetic manipulation and analysis in vertebrates
SI2002003T1 (en) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Gene vector comprising mi-rna
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
RU2435784C2 (en) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Obtaining antibodies from same heavy chains in transgenic animals
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US20090217397A1 (en) 2006-06-12 2009-08-27 Patrick Stern Cre-lox based gene knockdown constructs and methods of use thereof
US8084024B2 (en) 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
CN102719444B (en) 2006-09-01 2016-12-14 人类多细胞株治疗学公司 The expression that people or Humanized immunoglobulin strengthen in non-human transgenic animal
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2069403B1 (en) 2006-10-02 2014-05-07 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
WO2008112226A2 (en) 2007-03-13 2008-09-18 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
KR20140092232A (en) 2007-03-13 2014-07-23 내셔날 쥬이쉬 헬스 Methods for generation of antibodies
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
HUE037302T2 (en) 2007-06-01 2018-08-28 Open Monoclonal Tech Inc Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (en) 2007-07-27 2009-01-28 Areta Internat S R L IDIOTYPIC VACCINE
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
MX2010001684A (en) 2007-08-15 2010-04-21 Amunix Inc Compositions and methods for modifying properties of biologically active polypeptides.
EP2195346B1 (en) 2007-08-30 2018-01-03 The Walter and Eliza Hall Institute of Medical Research Dendritic cell marker and uses thereof
JP5933894B2 (en) 2007-09-14 2016-06-15 アディマブ， エルエルシー Rationally designed synthetic antibody libraries and their use
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス Antibodies against human NKG2D and uses thereof
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009114400A1 (en) 2008-03-07 2009-09-17 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
WO2009143472A2 (en) 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
DK3456190T3 (en) 2008-06-27 2022-02-14 Merus Nv ANTIBODY PRODUCING TRANSGENT MURINT ANIMALS
CA3038954A1 (en) 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8497325B2 (en) 2008-12-15 2013-07-30 Exxonmobil Chemical Patents Inc. Thermoplastic polyolefin blends and films therefrom
CN102292445A (en) 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 Non-human transgenic animals expressing humanised antibodies and use therof
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
WO2010128897A1 (en) 2009-05-07 2010-11-11 Volvo Construction Equipment Ab A working machine and a method for operating a working machine
RU2569187C2 (en) 2009-05-29 2015-11-20 МорфоСис АГ Collection and methods of its application
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
LT3241435T (en) 2009-07-08 2021-10-25 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
CN102803488A (en) 2009-11-17 2012-11-28 协和发酵麒麟株式会社 Human artificial chromosome vector
RU2603102C2 (en) 2009-12-10 2016-11-20 Ридженерон Фармасьютикалз, Инк. Mice that make heavy chain antibodies
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
MX350983B (en) * 2010-02-08 2017-09-27 Regeneron Pharma Common light chain mouse.
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
NO2905338T3 (en) 2010-06-22 2017-12-30
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
IN2013CN07629A (en) 2011-02-25 2015-08-07 Regeneron Pharma
RU2664232C2 (en) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
US20130044257A1 (en) 2011-08-18 2013-02-21 Lattice Energy Technology Corporation Mobile device with side-mounted camera module
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL2627773T3 (en) 2011-10-17 2017-11-30 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
EP3527070A1 (en) 2011-12-20 2019-08-21 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
SG11201404477YA (en) 2012-02-01 2014-08-28 Regeneron Pharma HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS
KR102171431B1 (en) 2012-04-20 2020-10-30 메뤼스 엔.페. Methods and means for the production of Ig-like molecules
US10238093B2 (en) 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN108611369B (en) 2013-03-13 2022-08-26 瑞泽恩制药公司 Mice expressing restricted immunoglobulin light chain repertoire
NL2012424C2 (en) 2013-03-13 2014-12-08 Regeneron Pharma Common light chain mouse.

Also Published As

Publication number Publication date
EP3572517B1 (en) 2021-03-24
US11357217B2 (en) 2022-06-14
EP2739740B1 (en) 2019-10-02
NZ727084A (en) 2022-08-26
NZ743520A (en) 2022-12-23
BR112014002713A2 (en) 2020-10-27
IL230766B (en) 2019-10-31
ES2758051T3 (en) 2020-05-04
HRP20192255T1 (en) 2020-03-06
JP6510234B2 (en) 2019-05-08
JP2014524243A (en) 2014-09-22
CN107602696B (en) 2022-05-13
CY1124341T1 (en) 2022-07-22
JP7174805B2 (en) 2022-11-17
JP2017006146A (en) 2017-01-12
EP2739740A1 (en) 2014-06-11
LT3572517T (en) 2021-04-26
ES2872081T3 (en) 2021-11-02
AU2015255276B2 (en) 2018-02-22
BR112014002713B1 (en) 2023-01-17
ZA201401006B (en) 2015-04-29
IL297371A (en) 2022-12-01
DK2739740T3 (en) 2019-12-09
AU2020277108A1 (en) 2020-12-24
AU2015255276A1 (en) 2016-01-28
CN103917650A (en) 2014-07-09
IL230766A0 (en) 2014-03-31
JP6886002B2 (en) 2021-06-16
MX2014001454A (en) 2014-06-04
AU2012294624A1 (en) 2013-05-02
EP3865581A1 (en) 2021-08-18
RS61946B1 (en) 2021-07-30
NZ710301A (en) 2017-05-26
US10130081B2 (en) 2018-11-20
CN103917650B (en) 2017-10-24
IL273982A (en) 2020-05-31
IL268413A (en) 2019-09-26
IL273982B2 (en) 2023-03-01
SG10201606158TA (en) 2016-09-29
WO2013022782A1 (en) 2013-02-14
HUE047278T2 (en) 2020-04-28
RU2664232C2 (en) 2018-08-15
PL3572517T3 (en) 2021-10-04
MX357623B (en) 2018-07-17
PT3572517T (en) 2021-06-23
MX2021001074A (en) 2022-06-14
DK3572517T3 (en) 2021-06-14
SI2739740T1 (en) 2019-12-31
EP3572517A1 (en) 2019-11-27
US20220394959A1 (en) 2022-12-15
AU2018203592B2 (en) 2020-12-10
JP2019062906A (en) 2019-04-25
PL2739740T3 (en) 2020-06-01
JP2020072695A (en) 2020-05-14
MY172718A (en) 2019-12-11
JP2021118746A (en) 2021-08-12
CN107602696A (en) 2018-01-19
NZ620586A (en) 2015-08-28
CA2844070A1 (en) 2013-02-14
PT2739740T (en) 2020-01-09
RS59728B1 (en) 2020-02-28
HUE055276T2 (en) 2021-11-29
AU2012294624B2 (en) 2015-08-13
RU2014108208A (en) 2015-09-10
CY1122435T1 (en) 2021-01-27
JP2023011882A (en) 2023-01-24
NZ781020A (en) 2023-01-27
JP6724126B2 (en) 2020-07-15
US20190133094A1 (en) 2019-05-09
LT2739740T (en) 2019-11-11
HRP20210916T1 (en) 2021-09-03
SG2014007686A (en) 2014-03-28
AU2018203592A1 (en) 2018-06-14
SI3572517T1 (en) 2021-09-30
IL273982B (en) 2022-11-01
US20130198879A1 (en) 2013-08-01
AU2020277108B2 (en) 2024-05-02
IL268413B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL273982A (en) Humanized universal light chain mice
IL266268B (en) Humanized light chain mice
IL292030B1 (en) Restricted immunoglobulin heavy chain mice